Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non-Small Cell Lung Cancer Patients
“Steroids were the biggest predictor of why certain immunotherapies may not be effective” – Dr. Fumito Ito
Non-Small Cell Lung Cancer (NSCLC)
CheckMate 77T: Perioperative Nivolumab Shows Long-Term EFS and ‘Favorable’ OS Trend in Resectable NSCLC
Perioperative nivolumab continued to demonstrate event-free survival benefits versus placebo in patients with resectable NSCLC.
FDA Greenlights Oral Therapy for NSCLC With EGFR Exon20 Insertion Mutations
FDA approves sunvozertinib for NSCLC with EGFR exon20 insertion mutations – first oral targeted therapy achieving 46% response rate.
FDA Greenlights Oral Therapy for NSCLC With EGFR Exon20 Insertion Mutations Read More »